Compare BioNTech SE - ADR (BNTX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Mesoblast Limited — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: BioNTech SE - ADR is far larger — about 10.5× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | MESO | |
|---|---|---|
Market Cap | $23.31B | $2.21B |
Sector | Health | Technology |
52-Week High | $119.34 | $20.96 |
52-Week Low | $83.89 | $12.88 |
Enterprise Value | $6.60B | $2.21B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
